🔴 Summit Therapeutics is trading 6.5% down today on a wider Q2 net loss and heavy R&D spending

Summit Therapeutics is trading 6.5% down at $14.01 after reporting a wider Q2 2026 net loss and reiterating plans for heavy R&D investment.

• The company emphasized commercial readiness and maintained guidance for elevated 2026 R&D expenses ahead of the ivonescimab PDUFA date.
• Cautious sentiment is being driven by the combination of high projected capital requirements and broader market weakness.